- CLSP-1025 targets the most common p53 mutation, a key oncogenic driver associated with multiple types of solid tumors, including gastrointestinal, lung, and gynecological cancers - Clasp's pHLAre™ ...
Clasp founder and CEO Tess Michaels joins Wealth! to discuss her mission of connecting students with employers who will invest in their education and careers. "I actually founded Clasp from a ...
CAMBRIDGE, Mass. & ROCKVILLE, Md.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), ...
If I didn’t like their watches so much, I’d probably be sick of hearing about Christopher Ward by now. The 20-year-old British independent brand has been on an incredible hot streak over the past two ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. CLASP inventor and founder/president of Endless Analog, Chris Estes. "We've gone from my ...
- Clasp's pHLAre™ platform is optimized for tumor-specific antigens, with the potential to yield safer and more effective precision immunotherapies - Preclinical data presented at the 2025 American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results